Promega

Promega, a US-based Pharmaceutical Preparation Manufacturing company, reported total carbon emissions of approximately 31,616 tonnes CO2e in 2024. This figure includes about 10,765 tonnes CO2e from Scope 1, 6,214 tonnes CO2e from Scope 2, and 14,637 tonnes CO2e from Scope 3 emissions. In the previous year, 2023, Promega's total emissions were approximately 37,073 tonnes CO2e, comprising about 10,732 tonnes CO2e for Scope 1, 9,227 tonnes CO2e for Scope 2, and 17,114 tonnes CO2e for Scope 3.

Promega has set near-term Science Based Targets initiative (SBTi) commitments to reduce its greenhouse gas emissions. The company aims to reduce absolute Scope 1 and Scope 2 GHG emissions by 46.9% by 2030, using 2023 as a base year. Additionally, Promega is committed to reducing absolute Scope 3 GHG emissions from capital goods and business travel by 42.0% within the same timeframe. Promega also targets that 67.0% of its suppliers, by emissions covering purchased goods and services and upstream transportation and distribution, will have science-based targets by 2030. These targets are classified as consistent with reductions required to keep warming to 1.5°C.